Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 65 kDa phosphoprotein (pp65), encoded by the UL83 gene of human cytomegalovirus (HCMV), is the most abundant tegument protein and a major structural component of mature viral particles. It plays a critical role in viral pathogenesis by modulating the host's immune system, specifically by counteracting the host antiviral response through the inhibition of interferon regulatory factor 3 (IRF3) nuclear translocation and the inactivation of the DNA sensor cGAS. Additionally, pp65 is involved in the transactivation of viral immediate-early genes and the proper assembly of viral particles. Because pp65 is highly immunodominant and frequently expressed in certain malignancies like glioblastoma and medulloblastoma, it has become a prominent therapeutic target.
Therapeutic strategies targeting pp65 include peptide-based vaccines, mRNA-loaded dendritic cell vaccines, and enveloped virus-like particles, which aim to stimulate a robust host T-cell-mediated immune response against CMV-infected or tumor cells. Adoptive cell therapies utilizing ex vivo expanded CMV-specific cytotoxic T lymphocytes (CTLs) are also being developed to treat CMV infections in immunocompromised transplant recipients. While targeting pp65 is highly promising for both infectious diseases and oncology, challenges include ensuring complete protection when targeted alone and managing potential immune-related adverse events.
Active immunotherapy (vaccines) designed to stimulate host helper and cytotoxic T-lymphocyte (CTL) responses against pp65-expressing cells, or adoptive cell therapy using ex vivo expanded CMV-specific T cells to target and destroy infected or tumor cells presenting pp65 epitopes.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 65 kDa phosphoprotein (pp65).